Distinguished in Cholangiocarcinoma (Bile Duct Cancer)

Haitao W. Zhao

160 Pujian Road, 
Shanghai, CN 
Distinguished in Cholangiocarcinoma (Bile Duct Cancer)
160 Pujian Road, 
Shanghai, CN 
OverviewLocationsClinical Research

Overview

Haitao Zhao practices in Shanghai, China. Zhao is rated as a Distinguished expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). Their top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Gallbladder Cancer, Hepatectomy, and Hepato-Pancreato-Biliary Surgery.

Their clinical research consists of co-authoring 482 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 47 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Locations

160 Pujian Road, Shanghai, 200127, China
Other Locations
1630 Dongfang Rd, Dongfang, 200127, China
No. 100 Kexue Avenue, Zhengzhou, 450001, China
1# Xikang Road, Nanjing, 210098, China
Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China
160 Pujian RD, Shanghai, 200127, China
139 Ziqiang Road, Shijiazhuang, 050051, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drug: ZW25 (Zanidatamab)
Study Phase: Phase 2
A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 20, 2025
Intervention Type: Drug
Study Drugs: AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets
Study Phase: Phase 3
View 1 Less Clinical Trial

482 Total Publications

Current status of management of immune-related adverse events and practical needs for oncologist education.
Current status of management of immune-related adverse events and practical needs for oncologist education.
Journal: Cancer biology & medicine
Published: September 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhao's expertise for a condition
ConditionClose
    View All 44 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile